A Study to Evaluate Triapine Combined with Lutetium Lu 177 Dotatate for Gastroenteropancreatic Neuroendocrine Tumors

Overview

About this study

The purpose of this study is to evaluate the safety and to determine the recommended phase 2 dose (RP2D) of Lutetium Lu 177 Dotatate in combination with triapine.

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Metastatic, histologically confirmed well-differentiated neuroendocrine tumor with positive gallium 68 Dotatate scan within 6 months. Lesions on gallium 68 Dotatate scan will be considered positive if the SUVmax is > 2 times SUV mean of normal liver parenchyma.
  • Failure of at least one prior systemic cancer treatment, including somatostatin analogs.
  • Patients must have progressive disease based on RECIST Criteria, Version 1.1 evidenced with CT scans/MRI obtained within 24 months from enrollment.
  • Patients must have measurable disease per RECIST 1.1.
  • No prior exposure to peptide receptor radionuclide therapy.
  • Recovered from adverse events of previously administered therapeutic agents to Grade 2 or less toxicity according to CTCAE version 5.0.
  • Archival tissue no longer than 6 months old should be present, otherwise baseline research biopsy is needed for WES.
  • Age ≥ 18 years.
  • Because no dosing or adverse event data are currently available on the use of triapine in combination with Lutetium Lu 177 Dotatate in patients <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.
  • ECOG performance status 0,1, or 2 (Karnofsky ≥ 60%).
  • Patients must have adequate organ and marrow function as defined below:
    • leukocytes                                     ≥ 2,000/mcL;
    • absolute neutrophil count              ≥ 1,500/mcL;
    • platelets                                         ≥ 75,000/mcL;
    • total bilirubin                                  ≤ 3 × institutional upper limit of normal (ULN);
    • AST(SGOT)/ALT(SGPT)               ≤  3 × institutional ULN;
    • glomerular filtration rate (GFR)     ≥ 50 mL/min using Cockroft-Gault method;
    • hemoglobin                                   ≥ 8.0 g/dL.
  • Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression.
  • Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen, in the opinion of the enrolling physician, are eligible for this trial.
  • Pregnancy Precaution: Men and women should avoid pregnancy for seven months after the date of their last treatment with Lutetium Lu 177 Dotatate. It is noteworthy that β- HCG may be secreted by a small percentage of NETs, such that, in addition to being a pregnancy marker, it also is a tumor marker. Consequently, NET female patients with positive β-HCG (>5 mIU/mL) at baseline can be eligible to enter the study and receive treatment if pregnancy can be excluded by lack of expected doubling of β-HCG and negative pelvic ultrasound. Normally, in pregnant subjects β-HCG doubles every 2 days during the first 4 weeks of pregnancy and every 3.5 days by Weeks 6 to 7. Women of childbearing potential include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral ovariectomy) or is not postmenopausal (defined as amenorrhea > 12 consecutive months, and for women on hormone replacement therapy, only with a documented plasma follicle-stimulating hormone (FSH) level > 35 mIU/mL). Even women who are using oral, implanted, or injected contraceptive hormones, an intrauterine device (IUD), or barrier methods (diaphragm, condoms, spermicidal) to prevent pregnancy, are practicing abstinence or where the partner is sterile (e.g., vasectomy) should be considered to be of childbearing potential. Postmenopausal women who have fertilized eggs implanted are also considered to be of childbearing potential. Acceptable methods of contraception may include total abstinence at the discretion of the Investigator in cases where the age, career, lifestyle, or sexual orientation of the patient ensures compliance.
  • Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception. Reliable contraception (hormonal or barrier method of birth control; abstinence) should be maintained throughout the study and for 7 months after study treatment discontinuation. All women of childbearing potential and male partners must use a double-barrier method of birth control or practice continuous abstinence from heterosexual contact throughout the study and for seven months after the end of the last treatment.
  • Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally- authorized representative (LAR) and/or family member available will also be eligible.

Exclusion Criteria:

  • Individuals < 18 years old.
  • Patients who have had major surgical procedures in the prior 6 weeks.
  • Patients with an inability to swallow oral medications or gastrointestinal disease limiting absorption of oral agents.
  • Patients who have received prior external beam radiotherapy to more than 50% of bone marrow, as determined by a radiation medicine physicist who will calculate the volume of bone marrow exposure in prior radiotherapy portals divided by the volume of total bone marrow harboring tissues. This ratio must be less than 50 percent.
  • Uncontrolled congestive heart failure (NYHA III, IV).
  • Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.
  • Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > Grade 1) with the exception of alopecia.
  • Patients who are receiving any other investigational agents.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to triapine or Lutetium Lu 177 Dotatate.
  • Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection; symptomatic decompensated congestive heart failure; unstable angina pectoris; cardiac arrhythmia; and known inadequately controlled hypertension.
  • Patients with psychiatric illness/social situations that would limit compliance with study requirements.
  • Pregnant women are excluded from this study because triapine is an RNR inhibitor and Lutetium Lu 177 Dotatate is a peptide receptor radionuclide therapy with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with triapine and Lutetium Lu 177 Dotatate, breastfeeding should be discontinued if the mother is treated with triapine and Lutetium Lu 177 Dotatate and for 2.5 months following the last treatment.
  • Discontinue long-acting somatostatin analogs (e.g., long-acting octreotide) for at least 4 weeks prior to initiating Lutetium Lu 177 dotatate. Long-acting somatostatin analog will be allowed to continue if patient has history of carcinoid syndrome and requires long- acting somatostatin analog for control of his/her functional syndrome.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Mohamad Sonbol, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Jacksonville, Fla.

Mayo Clinic principal investigator

Jason Starr, D.O.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

Thorvardur Halfdanarson, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20509123

Mayo Clinic Footer